Researchers published a Nature Communications paper reporting an RNA interference (RNAi) therapeutic that significantly reduces hepatitis B virus markers and advances toward a functional cure. The team described preclinical and translational data showing suppression of viral antigens and downstream immune-restorative effects. The paper details mechanism-of-action data and early safety signals that could fast-track combination strategies with existing antivirals. The study names key endpoints—sustained antigen decline and restoration of antiviral immunity—relevant to regulatory pathways for a functional HBV cure. Authors outline next steps including dose-optimization and combination trials to test whether RNAi plus immune modulators can achieve prolonged off-treatment virologic control. Clinicians and biotech investors should watch for upcoming early-phase trial readouts and partnering opportunities outlined by the authors and their institutions.